메티라폰
|
|
메티라폰 속성
- 녹는점
- 52-55 °C(lit.)
- 끓는 점
- 367.89°C (rough estimate)
- 밀도
- 1.0852 (rough estimate)
- 굴절률
- 1.6419 (estimate)
- 인화점
- >230 °F
- 저장 조건
- Inert atmosphere,Room Temperature
- 용해도
- H2O: 용해성(약간 용해됨)
- 산도 계수 (pKa)
- 4.61±0.10(Predicted)
- 물리적 상태
- 고체
- 물리적 상태
- 단단한 모양
- 색상
- 하얀색
- Merck
- 13,6181
- BRN
- 163023
- 안정성
- 제공된 대로 구매일로부터 2년 동안 안정적입니다. DMSO 또는 에탄올 용액은 -20°C에서 최대 2개월 동안 보관할 수 있습니다.
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
위험품 표기 | Xn | ||
---|---|---|---|
위험 카페고리 넘버 | 22-36/37/38 | ||
안전지침서 | 26 | ||
WGK 독일 | 3 | ||
RTECS 번호 | UC3050000 | ||
HS 번호 | 2933399090 | ||
유해 물질 데이터 | 54-36-4(Hazardous Substances Data) | ||
독성 | A well-known inhibitor of monooxygenase reactions and can also, under some circumstances, stimulate metabolism of xenobiotics in vitro. In either case, the effect is non-competitive, in that the KM does not change whereas Vmax does, decreasing in the case of inhibition and increasing in the case of stimulation. |
메티라폰 C화학적 특성, 용도, 생산
용도
Metyrapone acts as a glucocorticoid synthesis inhibitor, maintaining stress-hormone levels.생물학적 활성
Cytochrome P450 inhibitor. Blocks glucocorticoid synthesis via inhibition of steroid 11- β hydroxylase (CYP11B1) activity (IC 50 = 7.83 μ M). Also inhibits CYP3A4 and cytochrome P450-mediated ω / ω -1 hydroxylase activity.Mechanism of action
Metyrapone (Metopirone) produces its primary pharmacological effect by inhibiting 11-β-hydroxylase, thereby causing diminished production and release of cortisol. The resulting reduction in the negative feedback of cortisol on the hypothalamus and pituitary causes an increase in corticotrophin release and in the secretion of precursor 11-deoxysteroids.Clinical Use
Metyrapone is used in the differential diagnosis of both adrenocortical insufficiency and Cushing’s syndrome (hypercortisolism). The drug tests the functional competence of the hypothalamic–pituitary axis when the adrenals are able to respond to corticotrophin; that is, when primary adrenal insufficiency has been ruled out.After metyrapone administration, a patient with a disease of pituitary origin cannot achieve a compensatory increase in the urinary excretion of 17-hydroxycorticosteroids or 11-deoxysteroids. Moreover, if pituitary corticotrophin is suppressed by an autonomously secreting adrenal carcinoma, there will be no increase in response to metyrapone. On the other hand, if pituitary corticotrophin secretion is maintained, as occurs in adrenal hyperplasia, the inhibition of corticoid synthesis produced by metyrapone will stimulate corticotrophin secretion and the release of metabolites of precursor urinary steroids, which can be measured as 17-hydroxycorticosteroids. Metyrapone is now used less frequently in the differential diagnosis of Cushing’s syndrome because of the ability to measure plasma corticotrophin directly.
The steroid-inhibiting properties of metyrapone have also been used in the treatment of Cushing’s syndrome, and it remains one of the more effective drugs used to treat this syndrome. However, the compensatory rise in corticotrophin levels in response to falling cortisol levels tends to maintain adrenal activity.This requires that glucocorticoids be administered concomitantly to suppress hypothalamic–pituitary activity. Although metyrapone interferes with 11β- and 18- hydroxylation reactions and thereby inhibits aldosterone synthesis, it may not cause mineralocorticoid deficiency because of the compensatory increased production of 11-desoxycorticosterone.
부작용
Side effects associated with the use of metyrapone include gastrointestinal distress, dizziness, headache, sedation, and allergic rash. The drug should not be used in cases of adrenocortical insufficiency or when hypersensitivity reactions can be expected. When administered to pregnant women during the second or third trimesters, the drug may impair steroid biosynthesis in the fetus. Because metyrapone is relatively nontoxic, it is used in combination therapy with the more toxic aminoglutethimide to reduce its dosage.메티라폰 준비 용품 및 원자재
원자재
준비 용품
메티라폰 공급 업체
글로벌( 123)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Capot Chemical Co.,Ltd. | 571-85586718 +8613336195806 |
sales@capotchem.com | China | 29798 | 60 |
career henan chemical co | +86-0371-86658258 +8613203830695 |
sales@coreychem.com | China | 29888 | 58 |
SHANDONG ZHI SHANG CHEMICAL CO.LTD | +86 18953170293 |
sales@sdzschem.com | China | 2931 | 58 |
Chongqing Chemdad Co., Ltd | +86-023-6139-8061 +86-86-13650506873 |
sales@chemdad.com | China | 39916 | 58 |
Alchem Pharmtech,Inc. | 8485655694 |
sales@alchempharmtech.com | United States | 63711 | 58 |
Zhengzhou Alfa Chemical Co.,Ltd | +8618530059196 |
sale04@alfachem.cn | China | 13349 | 58 |
TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 |
marketing@targetmol.com | United States | 19892 | 58 |
Hefei TNJ Chemical Industry Co.,Ltd. | +86-0551-65418671 +8618949823763 |
sales@tnjchem.com | China | 34571 | 58 |
Shaanxi Dideu Medichem Co. Ltd | +86-029-89586680 +86-18192503167 |
1026@dideu.com | China | 8132 | 58 |
AFINE CHEMICALS LIMITED | +86-0571-85134551 |
info@afinechem.com | China | 15394 | 58 |
메티라폰 관련 검색:
1-페닐-1-에탄온 이소아밀아민 에틸피리딘-3
4-Methylpyrazole
Mitotan
Mycophenolate mofetil
Methylprednisolone
3-ISOBUTYLPYRIDINE
METYRAPONE
3-PROPIONYLPYRIDINE
3-PROPYLPYRIDINE
2-METHYL-1-(3-PYRIDINYL)-1-PROPANONE
3-(2-OXO-PROPYL)-PYRIDINIUM, CHLORIDE
PYRIDIN-3-YLACETALDEHYDE
Reduced metyrapone
metyrapone reductase
metyrapone N-oxide
Metyrapone Tartrate